DB Asset Management launches active ETF focused on new drug developers

Verifying
  • DB Asset Management listed the DB Mighty New Drug Focus Bio Active ETF on the Korea Exchange.
  • The fund uses FIC and BIC standards to select innovative drug-development companies.
  • DB Asset Management previously launched its Mighty Biosimilar & CDMO Active ETF in late 2024.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.